Anti-PD-1 ICIs (Pembrolizumab and nivolumab) have high response rate (about 80%) in Hodgkin’s disease, but intermediate response (10-45%) in melanoma, non-small cell lung carcinoma (NSCLC), bladder and urinary tract cancer, and triple-negative breast cancer (TNBC) patients (216, 219). This evidence concerns the gene PDCD1 and melanoma.